Conference Coverage

Staphylococcus aureus vaccine tolerable, immunogenic in preliminary study


 

AT IDWEEK 2015

References

SAN DIEGO – A vaccine designed to lower the risk of postoperative Staphylococcus aureus infections is being tested in a phase IIb study of adults who are preparing to undergo elective spinal fusion surgery.

In phase I-II trial results, reported at an annual scientific meeting on infectious diseases, the vaccine proved to be well tolerated, and it induced durable functional antibody responses.

The phase IIb trial aims to enroll 2,600 patients undergoing elective spinal fusion surgery, and is scheduled to end in 2017, said Dr. Buddy Creech of Vanderbilt University in Nashville, Tenn.

This scanning electron micrograph, under a very high magnification of 50,000x, shows a strain of Staphylococcus aureus bacteria taken from a vancomycin intermediate resistant culture. ©CDC/Janice Haney Carr

This scanning electron micrograph, under a very high magnification of 50,000x, shows a strain of Staphylococcus aureus bacteria taken from a vancomycin intermediate resistant culture.

“We’re at a point where the disease frequency of Staphylococcus aureus is high enough that we could make the case for universal vaccination,” said Dr. Creech. “If we can prove it in high-risk hosts, I think that’s a win.”

Invasive staphylococcal disease causes more deaths in the United States than AIDS, viral hepatitis, and tuberculosis combined, but the complex virulence factors of S. aureus have eluded vaccine researchers for years. Other investigational vaccines failed in previous large phase III trials. The tetravalent vaccine now being tested targets type 5 and 8 capsular polysaccharides (CP5 and CP8), which are expressed by 95% of hospital-associated S. aureus strains; an adhesion molecule; and an essential recombinant manganese transport protein C.

The vaccine was well tolerated in a phase I study of healthy adults earlier this year. Single doses of vaccine or placebo were administered to 285 healthy adults aged 65-84 years in a randomized, multicenter double-blind trial. Patients averaged 71 years in age, and half were women, Dr. Creech said at the combined annual meetings of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, and the Pediatric Infectious Diseases Society.

Similar rates of mild to moderate adverse events occurred in both groups, and no participants died or had serious vaccine-related side effects, Dr. Creech said.

At 1 month after vaccination, all tetravalent vaccine recipients and 5% of placebo recipients had achieved a predetermined threshold for CP5 opsonophagocytic activity. Likewise, about 92% of vaccinated recipients and 19% of placebo recipients achieved the CP8 opsonophagocytic activity threshold. Further, 84% of vaccinated recipients and none of the placebo recipients had at least a fourfold rise in antibody titers against the adhesion molecule.

In vaccine recipients, an immunoassay found substantial rises in antibodies against all four antigens by day 8; levels peaked around day 15, Dr. Creech said. “There was a decline of antibody titers over the course of the next year, as one would expect with a single-dose vaccine, but they remained over prespecified thresholds,” he added.

“Durability of response is especially important for patients who are scheduling surgeries and others who have a definitive risk period” for infection, he said.

Pfizer is funding the research, and Dr. Creech is a grant investigator for the company. One coauthor is also a grant investigator for Pfizer, nine coauthors are Pfizer employees and shareholders, and three declared no relevant conflicts of interest.

Recommended Reading

Shingles vaccine protection lasted 5-6 years in autoimmune disease patients
MDedge Family Medicine
Stroke risk rose in autoimmune disease patients after herpes zoster
MDedge Family Medicine
Answers elusive in quest for better chlamydia treatment
MDedge Family Medicine
HPV vaccinations not linked to CRPS and POTS in young women
MDedge Family Medicine
Sofosbuvir-velpatasvir combo effective in treatment-naive HCV patients*
MDedge Family Medicine
Sofosbuvir plus velpatasvir effective at treating HCV genotype 1 and 3 patients
MDedge Family Medicine
Shared decision making reduces antibiotic use
MDedge Family Medicine
Judicious antibiotic use key in ambulatory settings
MDedge Family Medicine
U.S congenital syphilis rates on the rise
MDedge Family Medicine
Progress toward measles elimination slows
MDedge Family Medicine